Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 and MVA HIV-1 Vaccines in Healthy African Adults
NCT04553016Phase 1Unknown
- Sponsor
- University of Oxford
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by University of Oxford. Primary endpoints: Local and systemic reactogenicity post vaccination at 7 days, Unsolicited Grade 3 or Grade 4 adverse events post vaccination at 28 days and 2 more. Status: unknown.
02
Drugs
ChAdOx1.tHIVconsv1MVA.tHIVconsv3MVA.tHIVconsv4
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04553016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553016.